フルテキストURL CCP_fulltext.pdf
著者 Tsukioki, Takahiro| Shien, Tadahiko| Tanaka, Takehiro| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| Toyooka, Shinichi|
キーワード Breast cancer Metformin Preoperative Tils CD8 PD-L1
発行日 2020-06-12
出版物タイトル Cancer Chemotherapy and Pharmacology
86巻 86巻
1号 1号
出版者 Springer
開始ページ 55 55
終了ページ 63 63
ISSN 0344-5704
NCID AA00598397
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 ©Author(s)
論文のバージョン Publisher
PubMed ID 32533334
DOI 10.1007/s00280-020-04092-2
Web of Science KeyUT 000539841500002
関連URL isVersionOf https://doi.org/10.1007/s00280-020-04092-2
フルテキストURL fulltext.pdf
著者 Shien, Tadahiko|
発行日 2019-03
出版物タイトル Translational Cancer Research
8巻
Suppl. 2号
出版者 AME Publishing
開始ページ S118
終了ページ S119
ISSN 2218-676X
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
論文のバージョン publisher
DOI 10.21037/tcr.2018.11.19
関連URL isVersionOf https://doi.org/10.21037/tcr.2018.11.19
フルテキストURL fulltext.pdf
著者 Shien, Tadahiko| Iwata, Hiroji|
キーワード breast cancer adjuvant neoadjuvant
備考 This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record TTadahiko Shien, Hiroji Iwata, Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology, Volume 50, Issue 3, March 2020, Pages 225–229 is available online at: https://doi.org/10.1093/jjco/hyz213.|
発行日 2020-01-28
出版物タイトル Japanese Journal of Clinical Oncology
50巻
3号
出版者 Oxford University Press
開始ページ 225
終了ページ 229
ISSN 0368-2811
NCID AA00690866
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 Copyright © 2020 Oxford University Press
論文のバージョン author
PubMed ID 32147701
DOI 10.1093/jjco/hyz213
Web of Science KeyUT 000536439500001
関連URL isVersionOf https://doi.org/10.1093/jjco/hyz213
著者 Iwamoto, Takayuki| Fujisawa, Tomomi| Shien, Tadahiko| Araki, Kazuhiro| Sakamaki, Kentaro| Sangai, Takafumi| Kikawa, Yuichiro| Takao, Shintaro| Nishimura, Reiki| Takahashi, Masato| Aihara, Tomohiko| Mukai, Hirofumi| aira, Naruto|
キーワード Metastatic breast cancer Endocrine therapies Estrogen receptor-positive HER2-negative Resistance
備考 This fulltext is available in May 2021.|
発行日 2020-05-11
出版物タイトル Breast Cancer
出版者 Springer
ISSN 13406868
NCID AA1103354X
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
論文のバージョン author
PubMed ID 32394413
DOI 10.1007/s12282-020-01095-y
Web of Science KeyUT 000531780600002
関連URL isVersionOf https://doi.org/10.1007/s12282-020-01095-y
フルテキストURL fulltext.pdf
著者 Takeda, Tatsuaki| Yamamoto, Hiromasa| Suzawa, Ken| Tomida, Shuta| Miyauchi, Shunsaku| Araki, Kota| Nakata, Kentaro| Miura, Akihiro| Namba, Kei| Shien, Kazuhiko| Soh, Junichi| Shien, Tadahiko| Kitamura, Yoshihisa| Sendo, Toshiaki| Toyooka, Shinichi|
キーワード breast cancer drug resistance lung cancer neratinib YES1
発行日 2019-12-19
出版物タイトル Cancer Science
111巻
3号
出版者 Wiley
開始ページ 849
終了ページ 856
ISSN 1347-9032
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2019 The Authors.
論文のバージョン publisher
PubMed ID 31856375
DOI 10.1111/cas.14289
Web of Science KeyUT 000507433400001
関連URL isVersionOf https://doi.org/10.1111/cas.14289
フルテキストURL fulltext.pdf
著者 Suzuki, Yoko| Taniguchi, Kohei| Hatono, Minami| Kajiwara, Yukiko| Abe, Yuko| Kawada, Kengo| Tsukioki, Takahiro| Kochi, Mariko| Nishiyama, Keiko| Iwamoto, Takayuki| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Tabata, Masahiro| Yanai, Hiroyuki| Doihara, Hiroyoshi|
キーワード Radiation-induced angiosarcoma Radiotherapy Breast-conserving surgery Breast cancer Paclitaxel therapy Adjuvant therapy of angiosarcoma
発行日 2020-01-16
出版物タイトル Surgical Case Reports
6巻
1号
出版者 SpringerOpen
開始ページ 25
ISSN 2198-7793
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © The Author(s). 2020
論文のバージョン publisher
PubMed ID 31950295
DOI 10.1186/s40792-020-0790-7
Web of Science KeyUT 000513920900001
関連URL isVersionOf https://doi.org/10.1186/s40792-020-0790-7
フルテキストURL OL17_2_2177.pdf
著者 Miyoshi, Yuichiro| Shien, Tadahiko| Ogiya, Akiko| Ishida, Naoko| Yamazaki, Kieko| Horii, Rie| Horimoto, Yoshiya| Masuda, Norikazu| Yasojima, Hiroyuki| Inao, Touko| Osako, Tomofumi| Takahashi, Masato| Tomioka, Nobumoto| Wanifuchi‑Endo, Yumi| Hosoda, Mitsuchika| Doihara, Hiroyoshi| Yamashita, Hiroko|
キーワード breast cancer estrogen receptor positive human epidermal growth factor receptor type 2 negative prognosis tumor infiltrating lymphocytes
発行日 2018-12-19
出版物タイトル Oncology Letters
17巻
2号
出版者 Spandidos Publications
開始ページ 2177
終了ページ 2186
ISSN 1792-1074
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
論文のバージョン publisher
PubMed ID 30675282
DOI 10.3892/ol.2018.9853
Web of Science KeyUT 000459551800096
関連URL isVersionOf https://doi.org/10.3892/ol.2018.9853
フルテキストURL BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf
著者 Saiga, Miho| Taira, Naruto| Kimata, Yoshihiro| Watanabe, Satoko| Mukai, Yuko| Shimozuma, Kojiro| Mizoo, Taeko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi|
キーワード BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction
発行日 2017-03
出版物タイトル Breast Cancer
24巻
2号
出版者 Japanese Breast Cancer Society
開始ページ 288
終了ページ 298
ISSN 1340-6868
NCID AA1103354X
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン author
PubMed ID 27179527
DOI 10.1007/s12282-016-0703-6
Web of Science KeyUT 000395524900012
関連URL isVerionOf https://doi.org/10.1007/s12282-016-0703-6
JaLCDOI 10.18926/AMO/54607
フルテキストURL 70_5_425.pdf
著者 Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
抄録 Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
キーワード breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
発行日 2016-10
出版物タイトル Acta Medica Okayama
70巻
5号
出版者 Okayama University Medical School
開始ページ 425
終了ページ 427
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27777441
Web of Science KeyUT 000388098700018
JaLCDOI 10.18926/AMO/54514
フルテキストURL 70_4_327.pdf
著者 Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
抄録 A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
キーワード metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
発行日 2016-08
出版物タイトル Acta Medica Okayama
70巻
4号
出版者 Okayama University Medical School
開始ページ 327
終了ページ 330
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549683
Web of Science KeyUT 000384748600018
JaLCDOI 10.18926/AMO/53907
フルテキストURL 69_6_333.pdf
著者 Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
抄録 We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
キーワード breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type Original Article
発行日 2015-12
出版物タイトル Acta Medica Okayama
69巻
6号
出版者 Okayama University Medical School
開始ページ 333
終了ページ 338
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26690243
Web of Science KeyUT 000368434500002
著者 Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro|
発行日 2013-12-01
出版物タイトル BMC Cancer
13巻
資料タイプ 学術雑誌論文
著者 Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos|
発行日 2014-01
出版物タイトル Breast Cancer Research and Treatment
143巻
2号
資料タイプ 学術雑誌論文
著者 Hayashi, Tatsuro| Asano, Hiroaki| Toyooka, Shinichi| Tsukuda, Kazunori| Soh, Junichi| Shien, Tadahiko| Taira, Naruto| Maki, Yuho| Tanaka, Norimitsu| Doihara, Hiroyoshi| Nasu, Yasutomo| Huh, Nam-ho| Miyoshi, Shinichiro|
発行日 2012-05
出版物タイトル Journal of Cancer Research and Clinical Oncology
138巻
5号
資料タイプ 学術雑誌論文
タイトル(別表記) Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
フルテキストURL 126_25.pdf
著者 溝尾 妙子| 枝園 忠彦| 伊藤 麻衣子| 野上 智弘| 岩本 高行| 元木 崇之| 平 成人| 松岡 順治| 土井原 博義|
抄録  Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.  Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.  Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.  Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
キーワード OSNA法(OSNA method) センチネルリンパ節(sentinel lymph node) micrometastases CK-19
出版物タイトル 岡山医学会雑誌
発行日 2014-04-01
126巻
1号
開始ページ 25
終了ページ 30
ISSN 0030-1558
関連URL http://www.okayama-u.ac.jp/user/oma/
言語 Japanese
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.126.25
JaLCDOI 10.18926/AMO/50409
フルテキストURL 67_3_165.pdf
著者 Shien, Tadahiko| Kinoshita, Takayuki| Seki, Kunihiko| Yoshida, Miwa| Hojo, Takashi| Shimizu, Chikako| Taira, Naruto| Doihara, Hiroyoshi| Akashi-Tanaka, Sadako| Tsuda, Hitoshi| Fujiwara, Yasuhiro|
抄録 While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to individualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response;pCR) and insensitive patients (clinical no change;cNC and clinical progressinve disease;cPD). In a comparison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p=0.045) and histological grade 3 (p=0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC.
キーワード breast cancer neoadjuvant chemotherapy predictors
Amo Type Original Article
発行日 2013-06
出版物タイトル Acta Medica Okayama
67巻
3号
出版者 Okayama University Medical School
開始ページ 165
終了ページ 170
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 23804139
Web of Science KeyUT Pretreatment Specimen Predicts
JaLCDOI 10.18926/AMO/50407
フルテキストURL 67_3_145.pdf
著者 Ishihara, Setsuko| Taira, Naruto| Kawasaki, Kensuke| Ishibe, Youichi| Mizoo, Taeko| Nishiyama, Keiko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Komoike, Yoshifumi| Sato, Shuhei| Kanazawa, Susumu|
抄録 A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, -0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, -0.196;p value, 0.0143) and number of deliveries (parameter estimate, -0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s.
キーワード breast cancer mammographic breast density life style body mass index
Amo Type Original Article
発行日 2013-06
出版物タイトル Acta Medica Okayama
67巻
3号
出版者 Okayama University Medical School
開始ページ 145
終了ページ 151
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 23804137
Web of Science KeyUT 000320747900003
関連URL http://ousar.lib.okayama-u.ac.jp/metadata/50646
著者 Nogami, Tomohiro| Shien, Tadahiko| Tanaka, Takehiro| Nishiyama, Keiko| Mizoo, Taeko| Iwamto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
発行日 2012-03-10
出版物タイトル Breast Cancer
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/48691
フルテキストURL 66_4_357.pdf
著者 Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Ikeda, Hirokuni| Nogami, Tomohiro| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
抄録 Ectopic thymoma is considered to arise from ectopic thymus tissue deposited as a result of the abnormal mislocalization of thymus tissue during the embryonic stage. An 86-year-old man visited our hospital with chief complaints of hoarseness and a mass in his anterior neck. A preoperative needle biopsy of the mass did not yield a definitive diagnosis. A positron emission tomography (PET) study revealed heterogeneous accumulation of <sup>18</sup>F-fluorodeoxyglucose (FDG) in the tumor. The tumor, affecting the left sternocleidomastoid muscle, the recurrent laryngeal nerve, the internal carotid vein, and the brachiocephalic vein, was resected using a combination of a collar incision in the neck and a median incision in the sternum. Immunohistochemically, the tumor was diagnosed as an ectopic thymoma of the neck. To date, only a few cases of ectopic thymoma presenting with FDG accumulation have been reported. Our experience indicates that ectopic thymoma should be kept in mind during the differential diagnosis of neck tumors with FDG accumulation appearing on PET images.
キーワード ectopic thymoma thyroid tumor positron emission tomography (PET)
Amo Type Case Report
発行日 2012-08
出版物タイトル Acta Medica Okayama
66巻
4号
出版者 Okayama University Medical School
開始ページ 357
終了ページ 361
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22918209
JaLCDOI 10.18926/AMO/46848
フルテキストURL 65_4_231.pdf
著者 Shien, Tadahiko| Doihara, Hiroyoshi| Nishiyama, Keiko| Masuda, Hiroko| Nogami, Tomohiro| Ikeda, Hirokuni| Taira, Naruto|
抄録 Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >12 months. The median TTP was 6 months (range:3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients;moreover, it yielded remarkable clinical responses.
キーワード metastatic breast cancer metronomic chemotherapy
Amo Type Original Article
発行日 2011-08
出版物タイトル Acta Medica Okayama
65巻
4号
出版者 Okayama University Medical School
開始ページ 231
終了ページ 237
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 21860529
Web of Science KeyUT 000294236700003